Denosumab, osteoporosis, and prevention of fractures

N Engl J Med. 2009 Nov 26;361(22):2188-9; author reply 2190-1. doi: 10.1056/NEJMc091893.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Biomarkers / blood
  • Bone Density Conservation Agents / adverse effects*
  • Bone Density Conservation Agents / therapeutic use
  • Denosumab
  • Female
  • Humans
  • Neoplasms / chemically induced*
  • Neoplasms / mortality
  • Osteoporosis, Postmenopausal / drug therapy*
  • Osteoprotegerin / blood
  • RANK Ligand / adverse effects*
  • RANK Ligand / antagonists & inhibitors*
  • RANK Ligand / blood
  • RANK Ligand / therapeutic use
  • Spinal Fractures / prevention & control

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • Bone Density Conservation Agents
  • Osteoprotegerin
  • RANK Ligand
  • TNFSF11 protein, human
  • Denosumab